Abstract:The aim of the present study was to compare the bioavailability of escitalopram (CAS 128196-01-0) from two escitalopram oxalate (CAS 219861-08-2) tablets (escitalopram 10 mg tablet as test preparation and 10 mg tablet commercially available original tablet of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 19 and 27. The study was conducted according to an open, randomized, single blind, 2-way crossover study design with a wash-out phase of 14 d. Blood samples for pharmacokinetic profiling were taken up to 156 h post-dose, and escitalopram plasma concentrations were determined with a validated liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method. Maximum plasma concentrations (C(max)) of 9.85 +/- 1.79 ng/ml (test) and 9.92 +/- 2.14 ng/ml (reference) were achieved. Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated. The median T(max) was 4.3 +/- 1.8h, 4.1 +/- 1.5 h for test and reference formulation, respectively. Plasma elimination half-lives (t 1/2) of 36.30 +/- 8.93 h (test), 36.70 +/- 9.99 h (reference) were determined. Both primary target parameters, AUC(0-infinity) and AUC(0-t) were tested parametrically by analysis of variance (ANOVA) and relative bioavailabilities were 105.1 +/- 10.8% for AUC(0-infinity), 104.9 +/- 11.1% for AUC(0-t). Bioequivalence between test and reference preparation was demonstrated for both parameters, AUC(0-infinity) and AUC(0-t). The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80%-125%. That means that the test formulation is bioequivalent to the reference formulation for escitalopram.

Bioequivalence of zopiclone tablet in Chinese healthy volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Studies on the Bioequivalence of Lorazepam Tablet in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Study on the bioequivalence of zolpidem tartrate in healthy Chinese vol unteers

Bioequivalence and Pharmacokinetics of Zolpidem Tartrate Mouth-dissolving Tablets

Pharmacokinetics and Bioequivalence of Lorazepam Tabletsin Chinese Healthy Volunteers

The pharmacokinetics of zopicolone tablet in 10 healthy male volunteers

Pharmacokinetics and Bioequivalence of Domestic Zolmitriptan Tablets in Chinese Healthy Volunteers

Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers

Pharmacokinetics and Bioequivalence of Zolmitriptan Tablets and Capsules in Chinese Healthy Volunteers

Study of the Bioequivalence of Gliclazide in Chinese Healthy Volunteers

Bioequivalence of Lisinopril Tablets in Health Volunteers

Bioequivalence Study of Voriconazole Tablet in Healthy Chinese Male Volunteers

Bioequivalence of Glipizide Controlled-Release Tablets in Chinese Healthy Volunteers

Bioequivalence of gliclazide tablets in Chinese healthy volunteers

Bioequivalent Study of Citalopram Tablets

Bioequivalence of oral sertraline hydrochloride tablets and dispersible tabletsin healthy volunteers

Bioequivalence of letrozole tablet in Chinese healthy volunteers

Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects under Fed and Fasting Conditions

Pharmacokinetics and bioequivalence of sertraline capsules and tablets